Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Jun Zhou,Wenjing Zhang,Yanping Zhang,Saifang Zheng,Luting Zhou,Xiaoqun Yang,Chaofu Wang

2022-01-01

American journal of translational research

Abstract:[This corrects the article on p. 6751 in vol. 12, PMID: 33194070.].

What problem does this paper attempt to address?

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Mei Kong,Zhaoming Wang,Xiaodong Teng,Liming Xu,Jimin Liu,Chenyang Jiang,Lisong Teng

2019-01-01

Abstract:[This corrects the article on p. 1674 in vol. 11, PMID: 31938268.].
Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

DOI: https://doi.org/10.1097/HS9.0000000000000987

2023-10-31

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000907.].
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

DOI: https://doi.org/10.1182/blood-2016-06-725010

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-04-639203.].
Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Hongzhi Li,Weihua Yuan,Shufang Bin,Guang Wu,Panyuan Li,Min Liu,Jifeng Yang,Xiang Li,Kaiyan Yang,Haihua Gu

2022-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 688 in vol. 10, PMID: 32195036.].
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Yuan Meng,Biping Deng,Luan Rong,Chuo Li,Weiliang Song,Zhuojun Ling,Jinlong Xu,Jiajia Duan,Zelin Wang,Alex H. Chang,Xiaoming Feng,Xiujuan Xiong,Xiaoli Chen,Jing Pan

DOI: https://doi.org/10.3389/fonc.2021.778039

IF: 4.7

2021-10-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.640166.].

oncology
Evaluation of the Clinicopathologic Features of Diffuse Large B Cell Lymphoma after CD19-targeted CAR T-cell Therapy Emphasizing the Potential Diagnostic Pitfalls.

Jun Zhou,Wenjing Zhang,Yanping Zhang,Saifang Zheng,Luting Zhou,Xiaoqun Yang,Chaofu Wang

2020-01-01

Abstract:Clinicopathologic data of 16 cases of DLBCL, NOS after CD19-targeted CAR T-cell therapy were retrospectively reviewed. Statistical analyses were performed to investigate the diagnostic agreement and indicate the relationship of the given types or their alterations (Group I versus Group II) to the prognosis. A total of 5 distinct histologic patterns were summarized. The CAR T cells were somewhat atypical, most of which were CD8 positive in the most cases (86.7%, 13/15), with a relatively high Ki-67 (60-90%). The rearrangement of BCR was demonstrated in all cases. The diagnostic test showed that the diagnostic accuracy in cases of types III (7%) and V (7%) was typically low; the diagnostic agreement in cases of type IV (for B, T, or nonlymphoma) and V (for T, or nonlymphoma) was consistently unsatisfactory. The rates of complete response (CR), partial response (PR), and progressive disease (PD) were 18.8% (3/16), 31.3% (5/16), 50% (8/16), respectively. In the follow-up, 25% (4/16) of cases experienced a recurrence and 31.3% (5/16) had died, of which 3 cases succumbed to the side effects. Group II had better disease-free survival (DFS, P=0.009). This study first described the pathologic features of DLBCL after CD19-targeted CAR T-cell therapy. Familiarity with these histologic features and combinations of medical history and genetic analyses facilitate avoiding misdiagnoses. Multiple biopsies are potentially helpful to estimate the treatment effects or prognosis, and stable alterations to any type of III to V, but not a single given one, may indicate a good prognosis.
Corrigendum: Interpreting flow cytometry with caution: a case report of follicular lymphoma in leukemic phase misdiagnosed as chronic lymphocytic leukemia

Yuan Ren,Congwei Jia,Miao Chen,Wei Wang,Wei Zhang

DOI: https://doi.org/10.3389/fonc.2023.1229649

IF: 4.7

2023-06-06

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2023.1170598.].

oncology
Correction: Unique CDR3 Epitope Targeting by CAR-T Cells is a Viable Approach for Treating T-cell Malignancies

Jinqi Huang,Stepanov Alexey,Jian Li,Terri Jones,Geramie Grande,Lacey Douthit,Jun Xie,Danna Chen,Xiaolei Wu,Maschan Michael,Changchun Xiao,Jiangning Zhao,Xuehua Xie,Jia Xie,Xiao Lei Chen,Guo Fu,Gabibov Alexander,Chi-Meng Tzeng

DOI: https://doi.org/10.1038/s41375-019-0484-y

2019-01-01

Leukemia

Abstract:In the original version of this article the author name Xiaolei Chen was published incorrectly. This has been corrected to Xiao Lei Chen.
Corrigendum to “Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma” [Genes Dis 6(4) 2019 407–418]

Junling Tang,Li Zhang,Tiejun Zhou,Zhiwei Sun,Liangsheng Kong,Li Jing,Hongyun Xing,Hongyan Wu,Yongli Liu,Shixia Zhou,Jingyuan Li,Mei Chen,Fang Xu,Jirui Tang,Tao Ma,Min Hu,Dan Liu,Jing Guo,Xiaofeng Zhu,Yan Chen,Ting Ye,Jianyu Wang,Xiaoming Li,H. Rosie Xing

DOI: https://doi.org/10.1016/j.gendis.2021.06.001

2022-01-01

Abstract:[This corrects the article DOI: 10.1016/j.gendis.2018.12.002.].

genetics & heredity,biochemistry & molecular biology
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Águeda Molinos-Quintana,Anna Alonso-Saladrigues,Blanca Herrero,Teresa Caballero-Velázquez,Víctor Galán-Gómez,Melissa Panesso,Montserrat Torrebadell,Javier Delgado-Serrano,Concepción Pérez de Soto,Anna Faura,Berta González-Martínez,Ana Castillo-Robleda,Cristina Diaz-de-Heredia,Antonio Pérez-Martínez,José María Pérez-Hurtado,Susana Rives,José Antonio Pérez-Simón

DOI: https://doi.org/10.3389/fimmu.2024.1373852

IF: 7.3

2024-02-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1280580.].

immunology
Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Yueyun Pan,Yinda Yu,Xiaojian Wang,Ting Zhang

DOI: https://doi.org/10.3389/fimmu.2021.775758

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2020.583084.].
Erratum to: CAR T Cell Therapy for Hematological Malignancies

Xin Yang,Gao-xiang Wang,Jian-feng Zhou

DOI: https://doi.org/10.1007/s11596-020-2280-3

2021-02-01

Current Medical Science

Abstract:The article “CAR T Cell Therapy for Hematological Malignancies”, written by Xin YANG, Gao-xiang WANG, Jian-feng ZHOU, was originally published electronically on the publisher’s internet portal on December 2019 without open access.

medicine, research & experimental
Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Zhongqing Zou,Tingting Guo,Jian Cui,Wenjiao Tang,Yan Li,Fangfang Wang,Tian Dong,Yunfan Yang,Yan Feng,Matthew Ho,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.7150/jca.79561

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:[This corrects the article DOI: 10.7150/jca.53209.].

oncology
Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Zhenyu Wei,Jiayu Xu,Chengkui Zhao,Min Zhang,Nan Xu,Liqing Kang,Xiaoyan Lou,Lei Yu,Weixing Feng

DOI: https://doi.org/10.3389/fimmu.2024.1379325

IF: 7.3

2024-02-08

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1273507.].

immunology
Erratum: PD-L1 expression in colon cancer and its relationship with clinical prognosis.

Tao Shan,Shuo Chen,Tao Wu,Yi Yang,Shunle Li,Xi Chen

2022-01-01

Abstract:[This corrects the article on p. 1764 in vol. 12, PMID: 31933995.].
Erratum: [Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy.

Jian Zhou,Yu Heng,Yue Yang,Xiaoke Zhu,Liang Zhou,Hongli Gong,Chengzhi Xu,Lei Tao

DOI: https://doi.org/10.3892/ol.2024.14456

2024-01-01

Oncology Letters

Abstract:[This corrects the article DOI: 10.3892/ol.2022.13554.].
Corrigendum: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma

Yicong Yao,Yi Wang,Denglong Wu,Baoying Hu

DOI: https://doi.org/10.3389/fonc.2021.731942

IF: 4.7

2021-07-21

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.666418.].

oncology
Corrigendum: Follicular lymphoma regulatory T-cell origin and function

Stéphane Rodriguez,Mehdi Alizadeh,Claire Lamaison,Alexis Saintamand,Céline Monvoisin,Rachel Jean,Laurent Deleurme,Jose Ignacio Martin-Subero,Céline Pangault,Michel Cogné,Patricia Amé-Thomas,Karin Tarte

DOI: https://doi.org/10.3389/fimmu.2024.1472373

2024-08-15

Abstract:[This corrects the article DOI: 10.3389/fimmu.2024.1391404.].

Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Erratum: Hepatic Carcinoma with Indolent T-lymphoblastic Proliferation (It-Lbp).

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Erratum: Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Evaluation of the Clinicopathologic Features of Diffuse Large B Cell Lymphoma after CD19-targeted CAR T-cell Therapy Emphasizing the Potential Diagnostic Pitfalls.

Corrigendum: Interpreting flow cytometry with caution: a case report of follicular lymphoma in leukemic phase misdiagnosed as chronic lymphocytic leukemia

Correction: Unique CDR3 Epitope Targeting by CAR-T Cells is a Viable Approach for Treating T-cell Malignancies

Corrigendum to “Identification and characterization of the cellular subclones that contribute to the pathogenesis of mantle cell lymphoma” [Genes Dis 6(4) 2019 407–418]

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Corrigendum: Tumor-Associated Macrophages in Tumor Immunity

Erratum to: CAR T Cell Therapy for Hematological Malignancies

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Erratum: PD-L1 expression in colon cancer and its relationship with clinical prognosis.

Erratum: [Corrigendum] Survival outcomes in patients with T3‑4aN0M0 glottic laryngeal squamous cell carcinoma and evaluation of postoperative radiotherapy.

Corrigendum: Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma

Corrigendum: Follicular lymphoma regulatory T-cell origin and function